ExpreS2ion Biotech Holding AB (publ) (STO: EXPRS2)

Sweden flag Sweden · Delayed Price · Currency is SEK
20.80
-1.20 (-5.45%)
Dec 27, 2024, 5:29 PM CET
-75.36%
Market Cap 43.27M
Revenue (ttm) 7.93M
Net Income (ttm) -34.01M
Shares Out 2.10M
EPS (ttm) -23.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,204
Open 22.00
Previous Close 22.00
Day's Range 19.90 - 22.00
52-Week Range 17.84 - 140.15
Beta 1.61
Analysts n/a
Price Target n/a
Earnings Date Feb 6, 2025

About STO: EXPRS2

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical compa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 21
Stock Exchange Nasdaq Stockholm
Ticker Symbol EXPRS2
Full Company Profile

Financial Performance

In 2023, EXPRS2's revenue was 8.80 million, an increase of 43.07% compared to the previous year's 6.15 million. Losses were -91.40 million, -22.94% less than in 2022.

Financial Statements

News

There is no news available yet.